Cause Of Alopecia Research Articles

Legislative efforts to expand insurance coverage of wigs for individuals with medical causes of alopecia

Legislative efforts to expand insurance coverage of wigs for individuals with medical causes of alopecia

The Value of Non-Cultured Adipose Derived Stem Cells (ADSCs) in Mechanically Micro Emulsified Adipose Tissue (Nanofat) together with Platelet-Rich Plasma (PRP) in Female Pattern Hair Loss (FPHL)

Abstract Background Female pattern hair loss (FPHL) is the most common cause of non- scaring alopecia in females and it significantly affects individuals' overall quality of life. Managing this condition poses a regular challenge in dermatological practice due to the limited supporting evidence for many therapeutic options, frequently resulting in unmet patient expectations. Nanofat grafts, generated by emulsification and filtering of microfat, contain growth factors and Adipose Derived Stem Cells (ADSCs) that can induce tissue regeneration and improve tissue quality Objective To assess the efficacy of Platelets Rich Plasma (PRP) added to Nanofat in Female Pattern Hair Loss (FPHL) Methods This is an Interventional study, which included 20 female patients with female pattern hair loss (FPHL) after exclusion of other causes of alopecia. Patients were selected from the outpatient clinic of Dermatology of Ain Shams University Hospitals from December 2022 till May 2023. Results In our study, 20 FPHL patients aging from 18 to 50 years. They were treated by Nanofat with PRP. They were followed up at12 and 24 weeks clinically by photography and trichoscopically by counting terminal and vellus hair and assessing the change in terminal and vellus hair thickness which were analyzed using image J data analysis software. Mean terminal hair count was increased highly significantly in number, as it increased from 73.90 hair/cm2 before treatment to 120.05 hair/cm2. There were high statistically significant decrease in vellus hair count, decreased from 46.60 to 25.20 (p < 0.001). There was high statistically significant increase in terminal hair thickness after treatment from 0.044 to 0.062 after 6months, (p < 0.001). There was high statistically significant increase in vellus hair thickness after treatment from 0.020 to 0.026 after 6 months from 0.020 to 0.023, p < 0.001 Conclusion The procedure seems safe, effective, well-tolerated by all the patients with encouraging response from these patients. We observed no adverse side effects in any. patient

Noninfectious causes of alopecia in the pediatric population.

To highlight recent advances in the knowledge base surrounding noninfectious causes of alopecia in the pediatric population. Recent developments in the literature included assessments of treatment efficacy, diagnostic utility of trichoscopy, and retrospective studies characterizing the clinical picture of pediatric cases. These findings will equip practitioners with the recent advances in the field's understanding of noninfectious causes of alopecia in the pediatric population.

Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study.

Telogen effluvium (TE) is the most common cause of alopecia in women. Treatment should address the etiological factors and may include adjuvant therapies. In practice, physicians may employ modified approaches and utilize various combinations of topical and oral molecules. In this real-life observational study, the aim was to evaluate the response of TE to iron supplementation. The population consisted of all patients who sought consultation for TE at our dermatology department between March 2021 and February 2022. Eligible participants were women, aged between 18 and 65, having a clinical diagnosis of TE, and intended for treatment with iron supplementation. Exclusion criteria comprised current pregnancy, chronic or active inflammatory disease, newly discovered dysthyroidism, concurrent use of hair supplements, topical minoxidil, or any other medications. The response was assessed based on the patient's level of satisfaction, a significant indicator, given the substantial psychological impact of TE on women's daily lives. The analysis included 200 women. The average age was 32.9 ± 11.4 years. A recent history of COVID-19 or treated dysthyroidism was present in 18.5% and 8% of patients, respectively, but did not impact their response. Significantly, patients with baseline ferritin ≥50 ng/ml were mostly "very satisfied", those with baseline ferritin <50 ng/ml were mostly "not satisfied", and those with unknown levels were mostly "partially satisfied" with iron supplementation. A high dose of elemental iron and a prolonged duration of treatment significantly improved the patients' level of satisfaction. Iron supplementation can improve the patient's level of satisfaction in TE even if serum ferritin is not low.

Role of oral minoxidil in the treatment of androgenetic alopecia

Patterned hair loss is the most common cause of alopecia, typically presenting with progressive thinning, miniaturization, and loss of hair at classical topography depending on the sex of the patient. In the 1970s, Minoxidil was used to treat severe refractory hypertension due to its vasodilator properties. It became popular after its coincidental finding on the promotion of hair growth and stimulation of new hair production. In 1988, the Food and Drug Administration approved topical minoxidil (TM) 2% for the treatment of male androgenetic alopecia and in 1992, for female pattern hair loss. It is also used as an off-label treatment for other hair loss conditions such as telogen effluvium and alopecia areata. However, there are frequent reports of TM-induced contact dermatitis and its reversible effect, which has reduced compliance in the patients and resulted in a poor outcome. Hence, they have studied using low-dose oral minoxidil (LDOM), which showed good efficacy and safety profile in the treatment of patterned hair loss along with avoidance of high-risk adverse cardiac effects that resulted due to doses used for hypertension. The added advantages of LDOM over topical formulation are good compliance, cost savings, effective in people with low hair follicle sulfotransferase activity, and the possibility of cotherapy with other topical or oral medications.

Modern Approaches to Treatment of Alopecia X in Dogs: Review of Research

Introduction. Noninflammatory alopecia is a disorder of canine appearance, which brings aesthetic discomfort to dog owners. Among foreign studies there are only few publications on implementing the drugs of the humane medicine for treatment of this disorder. The publications in the national literature present the descriptions of the individual clinical cases. The reviews of research containing the analysis and summary of the canine noninflammatory alopecia treatment methods are unavailable in the scientific literature. Therefore, this work aims at providing a comparative analysis of the canine noninflammatory alopecia treatment methods (based on the literature sources analysis).Materials and Methods. Searching by subject area was conducted in the eLIBRARY.RU, PubMed, Crossref and Google Scholar databases for materials published from 2000 to 2023 by the following keywords: dog AND alopecia, dog*AND alopecia X, dog*AND “name of the drug”. The selected materials were structured, 111 publications were analysed, 69 of which were included in the present review.Results. The studies on the use of humane medicine methods and drugs for treatment of alopecia X in dogs were analysed. The information was systemized into thematic blocks depending on the physiological causes of alopecia X and the drugs used. The main methods and approaches to be investigated were the use of melatonin, mitotane, trilostane, minoxidil, hormonal drugs, microneedling and microtrauma techniques.Discussion and Conclusion. Currently, the unified protocol for treatment of alopecia X in dogs is not developed in the veterinary medicine. Upon analysis of the treatment methods described in the literature, microneedling, oral administration of melatonin and trilostane, along with the use of subcutaneous implants of deslorelin acetate have been identified as the optimal ones, combining high efficiency with minor side effects. The use of mitotane, minoxidil and osaterone acetate causes the serious side effects, that prevents them from being the future-oriented methods.

An Analysis of Risk Factors of Recipient Site Temporary Effluvium After Follicular Unit Excision: A Single-Center Retrospective Study.

Temporary hair loss at the recipient site after hair restoration surgery is called shock loss (SL). This study analyzed the risk factors for SL among patients who received follicular unit excision. This study included 621 patients (554 males and 67 females). Twenty-three patients had SL (9 males and 14 females with a mean age of 40.8 years). The prevalence of SL was analyzed in relation to sex, age, graft follicular units, cause of alopecia, diabetes mellitus, smoking, drinking alcohol, and local anesthesia agent. Sex was identified as a risk factor for SL (odds ratio [OR]: 30.18; 95% confidence interval [CI] 9.43-96.55; p<0.001). Among female patients, age was identified as a risk factor for SL (OR:1.07; 95% CI 1.00-1.15; p=0.039). Over 40 years, the female pattern hair loss group had a significantly higher risk for SL than a female cosmetic group younger than 39 years. Sex was the only risk factor found for SL in this study. In addition, age was identified as a risk factor for SL among female patients. We believe our results provide information and risk factors for SL, not only for hair transplant surgeons, but also patients who will receive follicular unit excision. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

A Case Series of Trichotillomania; Impact of Therapeutic Intervention: Clinical Out-turn

Trichotillomania (TTM) is a less addressed cause of alopecia. Refusal to accept this condition as a psychiatric illness causes marked delay in seeking help. This article aims to evaluate the treatment response of TTM patients. This is a case series study on 5 patients (4 females, 1 male) of TTM, of whom 3 patients took treatment on an outpatient basis (obsessive-compulsive and related disorders clinic) and 2 patients at indoor (orange unit) at the Department of Psychiatry, Bangabandhu Sheikh Mujib Medical University, from January 2022 to July 2023. Out of 7 cases, 2 patients did not come after the 1stfollow-up. Pharmacological management was chosen according to established guidelines. All patients were given basic psychoeducation and relevant psychological intervention. A total of 5 cases were described. The median time to receive effective psychiatric treatment is 8.6 years (4–15 years). The median time to respond after starting therapy is 6 weeks. All patients responded well to selective serotonin reuptake inhibitors. Augmentation with low-dose antipsychotics and the addition of specific pharmacologic agents have been shown to improve outcomes. Psychological management helped patients most in achieving long-term remission. Despite the prolonged treatment gap, patients of TTM showed marked improvement with combined pharmacological and psychological intervention in a short time. Further study involving a more significant number of cases is needed to support the findings.

Baldness: Comprehensive aspects and its reassuring remedies

The medical term for baldness is alopecia. It refers to the condition where hair is lost from one or more areas of the body, commonly from the scalp. Balding can result from various factors, including genetic predisposition, environmental triggers, exposure to chemicals, medications, nutritional deficiencies, excessive stress, or prolonged illness. Depending on the pattern of hair loss and its underlying cause, alopecia is categorized into several types. Among these, androgenetic alopecia and alopecia areata are of primary concern. Presently, there are numerous synthetic treatments available for managing alopecia (both areata and androgenetic alopecia), including minoxidil, corticosteroids, zinc, dithranol, systemic cortisone, tretinoin, irritants, immunosuppressants, azelaic acid, and finasteride. However, these treatments often fail to provide satisfactory and long-lasting results for individuals with alopecia. Moreover, these synthetic products are associated with adverse effects, such as itching, redness, dermatitis, flaking, and irritation. Natural remedies have been explored to address the challenge of hair loss. A variety of herbs have demonstrated efficacy in managing alopecia. These natural remedies operate through mechanisms such as nutritional support, 5-α-reductase and DHT (dihydrotestosterone) inhibition, aromatherapy, and improved scalp blood circulation. Utilizing these natural treatments offers several advantages, including patient adherence, minimal side effects, easy accessibility, affordability, and diverse modes of therapeutic action for hair loss management. In this review, we highlighted the causes of alopecia and its promising, cost-effective treatments, which might significantly alter the lives of those impacted by baldness by providing them with a road to greater self-assurance, well-being, and quality of life.

Serum Ferritin Levels: A Clinical Guide in Patients With Hair Loss.

Ferritin is a key regulator of iron homeostasis that serves as an important clinical indicator of body iron status. Low serum ferritin is a highly specific and sensitive marker for diagnosing iron deficiency. In patients presenting with diffuse hair loss, serum ferritin may be a clinically useful tool for ruling out underlying iron deficiency as a cause of alopecia. As an acute-phase reactant, ferritin may be nonspecifically elevated in a wide range of inflammatory conditions; however, the role of ferritin in disorders of the skin and hair is not well understood. In this article, we review the structure and function of ferritin, and we provide a guide for clinical use.

Beard Alopecia: An Updated and Comprehensive Review of Etiologies, Presentation and Treatment.

Facial hair is an important social and psychologic aspect of clinical appearance for men. The purpose of this review is to provide a comprehensive overview of the causes of alopecia of the beard including the prevalence, pathophysiology, clinical presentation, and treatment. In this review, we highlight more common causes of beard alopecia including alopecia areata and pseudofolliculitis barbae, infectious causes such as tinea barbae and herpes simplex folliculitis, and rare causes including dermatopathia pigmentosa reticularis and frontal fibrosing alopecia. This review serves as an important resource for clinicians when faced with patients suffering from beard alopecia.

SARS-CoV-2 Infection-A Trigger Factor for Telogen Effluvium: Review of the Literature with a Case-Based Guidance for Clinical Evaluation.

Telogen effluvium post-COVID-19 is a condition characterized by the diffuse and reversible loss of scalp hair in the period following infection with SARS-CoV-2, and it is currently the second cause of alopecia in women. In the context of the COVID-19 infection, intense psychological stress contributes to alopecia appearance, along with systemic inflammation, autoimmune reactions, oxidative stress, and virally induced hypoxia. Cytokines with proinflammatory action and vasoactive substances negatively modulate the metabolism of some molecules, such as proteoglycans, involved in the hair follicle's growth cycle. Studies show that a large percentage of hairs will suddenly enter the catagen phase during a moderate to severe COVID-19 infection. In the present paper, we update the data from the literature with a clinical example. Our case highlighted that the telogen effluvium after infections with SARS-CoV-2 is reversible with appropriate dermatological treatment. For therapeutic success, informing the patient about this pathology's self-limited and reversible character is essential to reduce the emotional stress that may aggravate the disease.

Hairdressing Practices and Alopecia among Women Aged 15 to 45 in Bamako

Introduction: Alopecia is the pathological loss of hair, a frequent sign in dermatology whose etiologies are multifactorial. Alopecia in women can lead to a loss of self-esteem leading to depression and thus alter the quality of life. Better knowledge of the etiologies will make it possible to prevent certain types of alopecia in women and to improve case management. The aim of this work is to study the causes of alopecia in women aged 15 to 45 in the dermatology department of the National Center for Support in the Fight against Disease (CNAM). Methods: This was a descriptive cross-sectional study from February 2018 to February 2019, all women aged 15 to 45 consulting in the service during the study period. Case definition: alopecia any patient between the ages of 15 and 45 consulting for localized or diffuse hair loss. Results: We recruited 102 cases of alopecia out of 7223 women, i.e. a prevalence of 1.41%. The 25-35 age group represented 39%, with an average age of 28. Married women numbered 48, or 47.06%. Civil servants accounted for 28.43%. 87.25% of cases resided in urban areas. The duration of disease progression ranged from 1-12 months for 48.04% to 1-3 years for 36.28% and more than 3 years for 15.68%. The styling practices found in our cases: weaving, straightening, additions, represented respectively (97.06%, 53.92%, 72.54%); braids with addition every 04 weeks was practiced by 30 of our cases. Potash was used by 72.54% of cases for straightening. Our patients straightened their hair at a periodic rate of 3 months for 31.51% of cases, a rate of 6 months for 26.03% of cases. Alopecia was frontal seat, Traumatic alopecia was found in 33.33% of subjects practicing straightening. Rural women suffered from inflammatory causes (P=0.00005). Close straightening sessions expose to the risk of traumatic alopecia (P=0.03). Conclusion: The etiologies of alopecia are dominated by traumatic causes. This underlines the harmful effect of certain styling practices in ...

Platelet Rich Plasma Combination Therapies for Treatment of Androgenetic Alopecia: A Systematic Review.

Androgenetic alopecia (AGA) is the most common cause of alopecia in males and females. Minoxidil and finasteride are the only FDA-approved treatments for AGA. New treatments including Platelet Rich Plasma (PRP) and microneedling have shown promising results. The purpose of this literature review was to highlight recent studies examining the effects of topical minoxidil combined with PRP to minoxidil or PRP monotherapy. The method used for this paper includes a systematic review of the literature from 2010 to 2022 using the PubMed, EMBASE, and MEDLINE databases examining studies evaluating combination therapies for AGA. Three randomized control trials compared combination PRP + topical 5% minoxidil to either no treatment, 5% minoxidil, or PRP only. Two studies found increased hair growth at five months and at six months following combined therapy. Another study found an increase in hair density and improved patient satisfaction with combination therapy compared to monotherapy. A prospective study revealed that patients treated with combined 5% minoxidil, PRP, and microneedling reported the highest patient and physician satisfaction compared to minoxidil monotherapy. An observational study evaluating topical 5% minoxidil with PRP reported an increase in hair diameter after one year of combination treatment compared to minoxidil monotherapy. PRP therapy combined with minoxidil and microneedling in a retrospective study was shown to increase hair growth compared to PRP with minoxidil as well as PRP or minoxidil monotherapy. In conclusion, a variety of studies demonstrated superior treatment response with a combination of PRP and minoxidil therapy in patients with AGA. Limitations to this study include different PRP preparation protocols, few randomized control studies, and small sample sizes.

Antiseizure Medication-Induced Alopecia: A Literature Review.

Background: Adverse effects of antiseizure medications (ASMs) remain one of the major causes of non-adherence. Cosmetic side effects (CSEs) are among the most commonly reported side effects of ASMs. In this context, alopecia is one of the CSEs that has a high intolerance rate leading to poor therapeutical compliance. Methods: We performed a literature review concerning alopecia as a secondary effect of ASMs. Results: There are 1656 individuals reported with ASM-induced alopecia. Valproate (983), lamotrigine (355), and carbamazepine (225) have been extensively reported. Other ASMs associated with alopecia were cenobamate (18), levetiracetam (14), topiramate (13), lacosamide (7), vigabatrin (6), phenobarbital (5), gabapentin (5), phenytoin (4), pregabalin (4), eslicarbazepine (3), brivaracetam (2), clobazam (2), perampanel (2), trimethadione (2), rufinamide (2), zonisamide (2), primidone (1), and tiagabine (1). There were no reports of oxcarbazepine and felbamate with drug-induced alopecia. Hair loss seen with ASMs was diffuse and non-scarring. Telogen effluvium was the most common cause of alopecia. A characteristic feature was the reversibility of alopecia after ASM dose adjustment. Conclusions: Alopecia should be considered one important adverse effect of ASMs. Patients reporting hair loss with ASM therapy should be further investigated, and specialist consultation is recommended.

589 Platelet rich plasma combination therapies for treatment of androgenetic alopecia: A systematic review

Androgenetic Alopecia (AGA) is the most common cause of alopecia in males and females. Minoxidil and finasteride are the only FDA approved treatments for AGA. New treatments including Platelet Rich Plasma (PRP) and microneedling have shown promising results. The purpose of this literature review is to highlight recent studies examining the effects of topical minoxidil combined with PRP to minoxidil or PRP monotherapy. The method used for this paper include a systematic review of the literature from 2010 to 2022 using the PubMed, EMBASE, and MEDLINE databases examining studies evaluating combination therapies for AGA.

Herbal Therapy for the Treatment of Seborrhea Dermatitis.

Seborrhea dermatitis is a skin disorder that usually appears on parts of the body that have high density of sebaceous glands, such as the face, chest, and scalp. Clinical manifestations that generally appear as scaly skin and erythema. Seborrhea dermatitis is also known as one of the causes of alopecia. Treatments that can be used for seborrhea dermatitis are antifungal, anti-inflammatory, keratolytic, and coal tar. There are concerns about poor adherence, resistance, and some side effects of drugs that have been used in the treatment of seborrhea dermatitis. Concerns regarding these issues increase the urgency for the development of new therapeutic agents in the treatment of seborrhea dermatitis. Research on medicinal plants has enormous potential to produce compounds with new structures and bioactivity. This review discusses clinical and in vitro studies related to the activity of several medicinal plants that have potential as a treatment for seborrhea dermatitis, as well as the compounds that play a role in these activities. Literature searches were carried out on the PubMed, Taylor & Francis, and SpringerLink databases using Boolean Operators to get 25 articles that match the keywords used. Of the 25 articles, six were clinical trials, while 19 were in vitro studies of Malassezia. Several plants have potential as promising therapeutic agents for the treatment of seborrhea dermatitis by inhibiting the growth of Malassezia, decreasing sebum secretion, and decreasing symptoms associated with seborrhea dermatitis such as itching, pain or burning sensation, and redness.

Whole blood transcriptome profiling identifies candidate genes associated with alopecia in male giant pandas (Ailuropoda melanoleuca)

BackgroundThe giant panda (Ailuropoda melanoleuca) is a threatened species endemic to China. Alopecia, characterized by thinning and broken hair, mostly occurs in breeding males. Alopecia significantly affects the health and public image of the giant panda and the cause of alopecia is unclear.ResultsHere, we researched gene expression profiles of four alopecia giant pandas and seven healthy giant pandas. All pandas were approximately ten years old and their blood samples collected during the breeding season. A total of 458 up-regulated DEGs and 211 down-regulated DEGs were identified. KEGG pathway enrichment identified that upregulated genes were enriched in the Notch signaling pathway and downregulated genes were enriched in ribosome, oxidative phosphorylation, and thermogenesis pathways. We obtained 28 hair growth-related DEGs, and identified three hub genes NOTCH1, SMAD3, and TGFB1 in PPI analysis. Five hair growth-related signaling pathways were identified with abnormal expression, these were Notch, Wnt, TGF-β, Mapk, and PI3K-Akt. The overexpression of NOTCH1 delays inner root sheath differentiation and results in hair shaft abnormalities. The delayed hair regression was associated with a significant decrease in the expression levels of TGFB1.ConclusionsOur data confirmed the abnormal expression of several hair-related genes and pathways and identified alopecia candidate genes in the giant panda. Results of this study provide theoretical basis for the establishment of prevention and treatment strategies for giant pandas with alopecia.

In Silico Prediction of Metabolite in Petroselinum Crispum in Inhibiting Androgen Receptor as Treatment for Alopecia

Introduction: Alopecia is a hair loss that occur continuously and may occur in men, women and children. The causes of alopecia, including the use of cosmetics, medication, stress, postpartum period, hormonal disorders, and scalp infection. The purpose of this research is to determine the compounds contained in Petroselinum crispum that have the potential as antialopecia agents by predicting ligand-receptor binding and binding modes, predicting ADME by using Lipinski's rule, and also comparing the effectiveness with native ligand and minoxidil. Methodology: The process starts with protein and ligand structure preparation, then docking using Autodock Vina. Afterward, analyzed and visualized of the ligands docking, and predicted the ADME according to lipinski's rules using SwissADME and toxicity using PASS predistion. Result: There were 24 compounds found in Petroselinum crispum. Molecular docking simulation showed that six compounds had better binding affinities than minoxidil. Based on the results of prediction of ADMET values using the Lipinski rule and PASS Prediction, compound that are thought to have good activity is (+)–Marmesin compared to minoxidil. Conclusion: (+)–Marmesin to have better interactions with the androgen receptor, but not better than native ligands. thus, (+)–Marmesin can be used as antialopecia agents alternative terapy.

Early onset female pattern hair loss: A case–control study for analyzing clinical features and genetic variants

BackgroundFemale pattern hair loss (FPHL), the most common cause of alopecia in adult women, is classified into two subtypes: early onset and late onset (or postmenopausal). Little is known about the clinical features and genetic characteristics of early onset female pattern hair loss (eFPHL). ObjectivesTo investigate the clinical features and genetic characteristics of eFPHL. MethodsPatients with eFPHL and controls without eFPHL were prospectively recruited. The demographic and clinical features were collected. Single nucleotide polymorphisms (SNPs) located around the selected 30 candidate genes potentially associated with eFPHL were evaluated. ResultseFPHL patients (n = 63) manifested a decreased hair shaft density and cross-sectional area of the hair shaft compared to the control group (n = 341). eFPHL is associated with androgen-related features, including scalp greasiness, folliculitis, hirsutism, and polycystic ovary syndrome. Scalp pain and itching have been reported more frequently in patients with eFPHL. Forty-nine SNPs located around PPARGC1A, ABCC4, CYP11B2, FSHB, and CYP19A1 were found to be significant for eFPHL, including two PPARGC1A-associated SNPs: rs186530605 and rs192713767 (p = 3.94 × 10-11). ConclusionsThis study provided clinical features and genetic variants for eFPHL, which could provide insight into the underlying pathologic etiology. Considering the limited number of patients, a large-scale study is required in the future.